文献速递消化道肿瘤放疗放疗物理与技术

直肠癌新辅助放化疗后局部区域复发的剂量学与危险因素:ACCORD 12/0405-PRODIGE 02 研究

Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factors.
PubMed 文献 · Radiother Oncol · 2021-06-16

该研究基于 ACCORD 12/0405-PRODIGE 02 试验数据库,分析 39 例(6.5%)局部区域复发患者的临床、影像与剂量学数据,共 54 处复发灶。结果显示多数复发为野内(39%)或边缘(24%),仅 11% 为野外,复发集中于吻合口、直肠周围间隙及骶前/后侧方淋巴结引流区;低位直肠腺癌患者出现野外复发,降低低直肠肿瘤照射野上界增加野外复发风险,极低位肿瘤可考虑将腹股沟淋巴结纳入照射体积。

要点

  • 多数局部区域复发为野内或边缘复发,野外复发少见。
  • 复发部位集中在吻合口、直肠周围间隙及骶前/后侧方淋巴结。
  • 低直肠肿瘤照射野上界降低与野外复发风险增加相关。

核心结论

  • 降低低直肠肿瘤照射野上界会增加野外复发风险,极低位肿瘤可考虑将腹股沟淋巴结纳入照射体积。

研究设计与样本

  • 基于 ACCORD 12/0405-PRODIGE 02 试验数据库,识别局部区域复发患者并分析其临床、影像和剂量学数据。

主要发现

  • 39 例患者(6.5%)出现 54 处局部区域复发,其中野内 21 处(39%)、边缘 13 处(24%)、野外 6 处(11%),14 处无法评估。
  • 复发多数位于吻合口、直肠周围间隙及骶前和后侧方淋巴结引流区。
  • 仅接受低位直肠腺癌治疗的患者出现治疗体积外复发。
  • 2 例 T4 肿瘤延伸至前盆腔器官的患者出现前侧方和髂外淋巴结复发。

关键数值与推荐

  • 原文未报告剂量阈值、处方剂量或 delineation 推荐条款。

临床怎么用

  • 对低直肠肿瘤设计照射野时需权衡上界范围,避免因过度缩小上界而增加野外复发。
  • 极低位肿瘤可考虑将腹股沟淋巴结纳入照射体积。
  • 未来前瞻性试验应记录局部区域受累、治疗体积和复发区域以细化勾画指南。

局限性

  • 14 处复发无法评估剂量学,可能影响复发模式分类的完整性。
  • 为回顾性分析,样本量有限(39 例复发患者)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study is to correlate locoregional relapse with radiation therapy volumes in patients with rectal cancer treated with neoadjuvant chemoradiation in the ACCORD 12/0405-PRODIGE 02 trial. PATIENTS AND METHODS: We identified patients who had a locoregional relapse included in ACCORD 12's database. We studied their clinical, radiological, and dosimetric data to analyze the dose received by the area of relapse. RESULTS: 39 patients (6.5%) presented 54 locoregional relapses. Most of the relapses were in-field (n = 21, 39%) or marginal (n = 13, 24%) with only six out-of-field (11%), 14 could not be evaluated. Most of them happened in the anastomosis, the perirectal space, and the usual lymphatic drainage areas (presacral and posterior lateral lymph nodes). Only patients treated for a lower rectum adenocarcinoma had a relapse outside of the treated volume. 2 patients with T4 tumors extending into anterior pelvic organs had relapses in anterior lateral and external iliac lymph nodes. CONCLUSIONS: Lowering the upper limit of the treatment field for low rectal tumors increased the risk of out of the field recurrence. For very low tumors, including the inguinal lymph nodes in the treated volume should be considered. Recording locoregional involvement, treated volumes, and relapse areas in future prospective trials would be of paramount interest to refine delineation guidelines.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Meillan N, Orthuon A, Chauchat P, et al. Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factors. Radiother Oncol. 2021. PMID: 34144078. doi:10.1016/j.radonc.2021.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。